Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 3, 2011, Pages

  Tilghman, Myres W ^a   Guerena, Don Diego ^b   Licea, Alexei ^b,c   Pérez Santiago, Josué ^d   Richman, Douglas D ^a,e,f   May, Susanne ^g   Smith, Davey M ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Laborató Rio de Soluciones Genéticas   (Mexico)

^c CENTRO DE INVESTIGACIÓN CIENTÍFICA Y DE EDUCACIÓN SUPERIOR DE ENSENADA   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV; pooling; resource limited settings; viral loads; virologic failure

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ALGORITHM; ARTICLE; CLINICAL EVALUATION; CONTAMINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEXICO; NUCLEIC ACID ANALYSIS; PLASMA; POOLED NUCLEIC ACID TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

DRUG MONITORING; HIV; HIV INFECTIONS; HUMANS; MEXICO; PLASMA; RNA, VIRAL; SPECIMEN HANDLING; TREATMENT FAILURE; VIRAL LOAD;

EID: 79951802517     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ff63d7     Document Type: Article

References (25)

1. Bagnarelli P, Menzo S, Valenza A, et al. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J Clin Microbiol. 1995; 33:16-23. (Pubitemid 24382390)
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society- USA panel. JAMA. 2010;304:321-333.
3. Bendavid E, Young SD, Katzenstein DA, et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med. 2008;168:1910-1918.
4. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resourcelimited regions: optional or necessary? Clin Infect Dis. 2007;44:128-134. (Pubitemid 44968997)
5. Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371:1443-1451. (Pubitemid 351635534)
6. Schooley RT. Viral load testing in resource-limited settings. Clin Infect Dis. 2007;44:139-140. (Pubitemid 44968999)
7. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505-510. (Pubitemid 44142772)
8. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971-1977.
9. Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;49: 477-484.
10. Koenig SP, Kuritzkes DR, Hirsch MS, et al. Monitoring HIV treatment in developing countries. BMJ. 2006;332:602-604. (Pubitemid 44365763)
11. van Oosterhout JJ, Brown L, Weigel R, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health. 2009;14:856-861.
12. UNAIDS/WHOWorking Group on Global HIV/AIDS and STI Surveillance. STI UWWGoGHAa. UNAIDS/WHO Epidemiological Fact Sheets on HIV and AIDS, 2008 Update. 2008. Available at: http://apps.who.int/globalatlas/ predefinedReports/EFS2008/ full/EFS2008-MX.pdf. Accessed November 2010.
13. Brouwer KC, Strathdee SA, Magis-Rodriguez C, et al. Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health. 2006;83:299-307. (Pubitemid 44341581)
14. Strathdee SA, Magis-Rodriguez C. Mexico's evolving HIV epidemic. JAMA. 2008;300:571-573.
15. Salud Sd. Rendición de Cuentas en Salud 2008. 2009;1:73-78. Available at: http://portal.salud.gob.mx/descargas/pdf/rcs2008.pdf. Accessed November 2010.
16. Smith DM, May SJ, Perez-Santiago J, et al. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS. 2009;23: 2151-2158.
17. May S, Gamst A, Haubrich R, et al. Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr. 2010;53:194-201.
18. Hourfar MK, Jork C, Schottstedt V, et al. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus- 1, hepatitis C virus, and hepatitis B virus. Transfusion. 2008;48: 1558-1566.
19. Ma Y, Zhao D, Yu L, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis. 2010;50:264-271.
20. Ndembi N, Goodall RL, Dunn DT, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine- lamivudine plus Abacavir. J Infect Dis. 2010;201:106-113.
21. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapinebased initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008;22:2117-2125.
22. Giordano TP, Guzman D, Clark R, et al. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79. (Pubitemid 38697081)
23. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102. (Pubitemid 38989377)
24. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47: 266-285. (Pubitemid 351920631)
25. Brambilla D, Reichelderfer PS, Bremer JW, et al. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS. 1999;13: 2269-2279. (Pubitemid 29531446)